Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...

MILAN — Photodynamic diagnosis-guided transurethral resection of bladder tumors did not reduce recurrence rates of non–muscle-invasive bladder cancer (NMIBC) in the longer term compared with standard ...

Please provide your email address to receive an email when new articles are posted on . Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Investigators observe no significant difference between the surgical approaches in 1-year progression rates. En bloc resection has the potential to improve outcomes in patients with non-muscle ...

“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...

Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy. Patients with nonmetastatic ...

UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...